MK-677: Clinical Guide for Prescribing Practices
MK-677 (Ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics the action of ghrelin at the GH secretagogue receptor. While not technically a peptide, it is commonly grouped with peptide therapies due to its GH-stimulating effects and is popular for its oral route of administration.
Also Known As
How MK-677 Works
MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that functions as a potent, orally active ghrelin receptor (GHS-R1a) agonist [2]. It mimics ghrelin's stimulatory effect on anterior pituitary somatotrophs, increasing both basal and pulsatile GH secretion [3]. Unlike injectable peptide secretagogues, MK-677 achieves high oral bioavailability (approximately 60%) and has a long elimination half-life (4 to 6 hours with extended GH effects lasting up to 24 hours), enabling convenient once-daily oral dosing [2].
Clinical Evidence
A landmark 2-year randomized controlled trial demonstrated that MK-677 at 25mg daily significantly increased GH and IGF-1 levels to those of young adults in elderly subjects, with improvements in fat-free mass and no significant change in visceral fat [1]. Murphy et al. demonstrated dose-dependent oral bioavailability and sustained IGF-1 elevation over 14 days of dosing [2]. Studies in GH-deficient adults showed MK-677 increased IGF-1 by 40 to 60% within 2 weeks [3]. Metabolic concerns include increased fasting glucose and insulin resistance, particularly with prolonged use [1].
Clinical Uses
Patient Selection and Screening
Best candidates are patients who cannot tolerate or refuse injections, those seeking GH optimization with maximum convenience, and patients where compliance with injectable protocols has been problematic [2]. Also useful for older adults with documented GH decline who prefer oral therapy [1]. Avoid in patients with uncontrolled diabetes, insulin resistance, or metabolic syndrome due to glucose-elevating effects [1]. Screen with fasting glucose, fasting insulin, HbA1c, IGF-1, and comprehensive metabolic panel. Caution in patients prone to edema or with CHF risk.
Dosing and Administration
Standard dosing is 10 to 25mg orally once daily, taken in the evening (to align GH peak with natural nocturnal secretion and minimize daytime hunger) [4]. Start at 10mg for 2 to 4 weeks to assess tolerability, then titrate to 25mg if needed [2]. The long half-life supports once-daily dosing. Continuous use protocols typically run 3 to 6 months with periodic metabolic monitoring [1]. Some clinicians cycle 8 to 12 weeks on, 4 weeks off. Monitor fasting glucose and insulin at baseline, week 4, and quarterly. Reduce dose or discontinue if fasting glucose exceeds 110 mg/dL or HbA1c rises above 5.7% [1]. All dosing decisions require physician clinical judgment.
Route: Oral
Protocol notes: Oral administration, typically 10-25mg daily, taken in the evening. Long half-life allows once-daily dosing.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
MK-677 offers a unique oral delivery advantage that appeals to injection-averse patients, expanding the addressable market for GH optimization programs [2]. Wholesale cost for oral capsules is typically $20 to $50 per month supply. Patient pricing ranges from $150 to $350 per month. The oral format reduces pharmacy handling complexity and eliminates the need for injection training or supplies. However, metabolic monitoring requirements (glucose, insulin) mean more frequent lab visits [1], which can be billed separately and add to program revenue.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe MK-677 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What advantages does MK-677 have over injectable GH peptides?
What are the metabolic concerns with MK-677?
References
- Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611
- Murphy MG et al. Oral administration of the growth hormone secretagogue MK-677 increases IGF-I in healthy adults. J Clin Endocrinol Metab. 1998;83(4):1157-1162
- Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677). J Clin Endocrinol Metab. 1996;81(12):4249-4257
- Copinschi G et al. Effects of a 7-day treatment with MK-677 on 24-hour GH profiles. Eur J Endocrinol. 1997;136(6):628-635
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe MK-677 Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe MK-677 Through Karpa